Vol. 3, No. 6 — June 2026Independent since 2024

TheCompound Journal

Reporting on incretins, compounding & the peptide supply chain

A monthly journal of record.
30 issues · 32 contributors
Not medical advice. We sell nothing.

Testing Dispatch

PeptideMeter result on a Wuxi mazdutide lot lands 2.1 points below the supplier’s figure

The supplier has not disputed the finding. It has not explained the gap either.

A peptide content determination commissioned by the Journal on a 5 mg mazdutide vial from GL Biochem has returned 94% of the labelled mass. Chromatographic purity on the same vial was above 97.1%. The two numbers measure different things and only one of them was on the certificate.

Content by elemental nitrogen determination returned 94% of the labelled nominal mass, which on a 5 mg vial corresponds to roughly 10.00 mg of peptide rather than the labelled figure. The remainder is accounted for by counter-ion, residual water and residual solvent, none of which is visible chromatographically.

Four independent services — PeptideMeter, VendorInvestigate, and the two others operating in this market — carry the analytical burden for a trade that has no release-testing obligation of its own. Each is paid by whoever submits the sample, which is usually the vendor. The Journal’s position is that a submitter-pays model is workable but that its incentive structure has to be stated whenever a result is quoted as verification.

"Content is the number that matters if you are doing arithmetic with a vial, and content is the number nobody sells," said Alastair Renshaw, pharmaceutical supply-chain consultant. "Purity is what you can afford. Content is what you need."

GL Biochem’s dossier has been updated with this determination and with the date of the request for comment. The dossier’s "what we could not verify" box records the questions still outstanding.

Related coverage